Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ESSA Pharma ( (EPIX) ) has shared an update.
On July 31, 2025, ESSA Pharma Inc. informed its shareholders about the potential U.S. and Canadian federal income tax implications of an initial cash distribution related to its business combination with XenoTherapeutics, Inc. The company plans to reduce the capital of its common shares and distribute the amount to shareholders as part of its winding-up process, subject to court approval. The announcement highlights the tax considerations for U.S. holders and the uncertainties surrounding the distribution’s timing and amount.
The most recent analyst rating on (EPIX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. operates in the pharmaceutical industry, focusing on developing therapies for cancer treatment. The company is engaged in a business combination agreement with XenoTherapeutics, Inc.
Average Trading Volume: 214,780
Technical Sentiment Signal: Sell
Current Market Cap: $83.01M
See more data about EPIX stock on TipRanks’ Stock Analysis page.